Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Century Therapeutics, Inc. Common Stock (IPSC)

Biological Products, (no Disgnostic Substances)

https://www.centurytx.com

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.

25 N 38TH STREET, 11TH FLOOR
PHILADELPHIA, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/18/2021

Market Cap

134,274,860

Shares Outstanding

59,840,000

Weighted SO

59,834,968

Total Employees

N/A

Upcoming Earnings

08/14/2024

Beta

1.4000

Last Div

0.0000

Range

1.28-5.51

Chg

-0.0750

Avg Vol

269479

Mkt Cap

134274860

Exch

NASDAQ

Country

US

Phone

267 817 5790

DCF Diff

1.5656

DCF

0.0444

Div Yield

0.0000

P/S

65.7565

EV Multiple

-1.2934

P/FV

0.5858

Div Yield %

0.0000

P/E

-0.9903

PEG

0.7493

Payout

0.0000

Current Ratio

10.6183

Quick Ratio

10.6183

Cash Ratio

2.1634

DSO

314.4148

DIO

0.0000

Op Cycle

314.4148

DPO

101.9099

CCC

212.5049

Gross Margin

-4.8898

Op Margin

-65.1758

Pretax Margin

-64.4667

Net Margin

-64.3423

Eff Tax Rate

0.0019

ROA

-0.3155

ROE

-0.6537

ROCE

-0.3350

NI/EBT

0.9981

EBT/EBIT

0.9891

EBIT/Rev

-65.1758

Debt Ratio

0.1354

D/E

0.2538

LT Debt/Cap

0.1918

Total Debt/Cap

0.2024

Int Coverage

123.2306

CF/Debt

-1.7287

Equity Multi

1.8750

Rec Turnover

1.1609

Pay Turnover

3.5816

Inv Turnover

0.0000

FA Turnover

0.0208

Asset Turnover

0.0049

OCF/Share

-1.1872

FCF/Share

-1.2487

Cash/Share

2.3925

OCF/Sales

-47.7272

FCF/OCF

1.0518

CF Coverage

-1.7287

ST Coverage

-26.6063

CapEx Coverage

-19.3026

Div&CapEx Cov

-19.3026

P/BV

0.5858

P/B

0.5858

P/S

65.7565

P/E

-0.9903

P/FCF

-1.3099

P/OCF

-1.3351

P/CF

-1.3351

PEG

0.7493

P/S

65.7565

EV Multiple

-1.2934

P/FV

0.5858

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 22, 21:30 Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - Exclusive Report by Transparency Market Research, Inc. MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks Benzinga Dec 19, 17:05 Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 09, 12:00 Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasionâ„¢ Edits GlobeNewswire Inc. Dec 06, 07:30 Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus GlobeNewswire Inc. Dec 06, 07:30 Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

Revenue Product Segmentation